Peptides

Control of body energy use through brain GIP receptor signals

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Agonism and antagonism of the GIP receptor may improve metabolic outcomes when used alongside GLP-1 receptor agonism.

  • GLP-1 receptor agonism is widely recognized for its pharmacological benefits in combating obesity.
  • The role of the GIP system in metabolic regulation remains controversial, despite evidence supporting its beneficial effects.
  • Both GIP receptor agonism and antagonism have shown positive metabolic effects in preclinical and clinical studies.
  • There is accumulating evidence suggesting that GIP may have beneficial metabolic effects through its action in the brain.
  • Uncertainty exists regarding the specific locations and mechanisms of GIP action in the brain related to metabolism.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Conflict of Interest TDM receives research funding from Novo Nordisk, but these funds are unrelated the here described work. TDM further received speaking fees within the last 3 years from Novo Nordisk, Eli Lilly, AstraZeneca, Merck, Berlin Chemie AG, and Mercodia.
PubMed

Related papers

Mar '24
Loss of GIP receptor in leptin receptor cells reduces glucose control by GIP and GIP-GLP-1 combination without changing body weight or food intake in mice
top 5% journal
cited by 11 papers
research support, non-u.s. gov't
Dec '18
Improved GIP-like drugs reduce body weight in mice by activating, not blocking, GIP receptors
top 5% journal
cited by 206 papers
research support, non-u.s. gov't
Dec '20
Targeting the GIP receptor for obesity: Should it be activated or blocked? Possible ways it works
top 5% journal
cited by 114 papers
research support, n.i.h., extramural
May '20
Drug effects of single, double, and triple peptide activators on GIP and GLP-1 hormone receptors
top 10% journal
cited by 51 papers
research support, non-u.s. gov't
Jul '24
How Incretin Hormones Help Regulate Heart Energy Use
cited by 1 paper
journal article
Feb '23
Fat around the human heart contains receptors for glucose-related hormones that could be targets for multiple treatments
top 5% journal
cited by 83 papers
research support, non-u.s. gov't
Sep '14
The GIP receptor is more active at rest than the GLP-1 receptor but less effective at attracting GRK2 or arrestin3 proteins
top 30% journal
cited by 47 papers
research support, non-u.s. gov't
May '16
Treating diabetes and obesity by activating two hormone receptors called 'twincretins'
cited by 53 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief